uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Thirteen of 17 analysts rate uniQure a buy, with an average 12-month price target of $65.00 versus the reported $45.36 share price.
• Recent analyst actions were mostly positive, including Wells Fargo raising its target to $75, RBC to $65 and Chardan Capital to $37; however, Weiss Ratings and Wall Street Zen maintained or issued sell ratings.
• Financial results remain challenging: uniQure missed quarterly EPS estimates, reporting a loss of $1.22 per share versus expectations of $0.82, while insiders sold $16.8 million of stock over the past three months. Institutional investors own 78.83% of the shares.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seventeen analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $65.00.

Several brokerages recently weighed in on QURE. Wells Fargo & Company lifted their price target on uniQure from $60.00 to $75.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Chardan Capital raised their price objective on uniQure from $31.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, April 30th. Royal Bank Of Canada boosted their price objective on uniQure from $35.00 to $65.00 and gave the company an "outperform" rating in a research report on Thursday, June 18th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of uniQure in a research note on Friday, June 26th. Finally, Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st.

Insider Activity at uniQure

In other news, insider Walid Abi-Saab sold 30,000 shares of the business's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the completion of the sale, the insider owned 148,235 shares of the company's stock, valued at $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O'keefe sold 15,936 shares of the company's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $431,228.16. Following the transaction, the insider owned 108,864 shares of the company's stock, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 388,229 shares of company stock valued at $16,817,099 in the last three months. Company insiders own 4.65% of the company's stock.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the company. Woodline Partners LP raised its holdings in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of uniQure during the second quarter worth approximately $497,000. Marshall Wace LLP increased its position in shares of uniQure by 276.5% during the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company's stock worth $3,108,000 after purchasing an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new position in uniQure in the 2nd quarter valued at $540,000. Finally, Ameriprise Financial Inc. raised its stake in uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company's stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Up 2.5%

QURE stock opened at $45.36 on Friday. uniQure has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The firm's fifty day moving average is $39.05 and its 200 day moving average is $26.90. The firm has a market cap of $3.15 billion, a PE ratio of -11.31 and a beta of 0.92.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter last year, the company posted ($0.69) EPS. On average, research analysts forecast that uniQure will post -3.74 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source